Arcturus Nets EU mRNA Vaccine Approval and CSL Seqirus Partnership Amid 53% YTD Stock Slump
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) is a biotechnology company based in San Diego, California, specializing in RNA medicines. Founded in 2013, the company focuses on lipid-nanoparticle delivery of messenger RNA (mRNA) and self-amplifying mRNA (sa-mRNA) therapeutics. Its pipeline addresses liver and respiratory rare diseases, including ornithine transcarbamylase deficiency and cystic fibrosis, as well as vaccine candidates for COVID-19 and influenza.
Corporate Structure
Headquartered in San Diego, California, Arcturus employs between 51 and 200 professionals in research, development, and manufacturing operations. The company's leadership team possesses extensive experience in biotechnology and pharmaceutical development. Proprietary platforms include LUNAR lipid-mediated delivery and STARR sa-mRNA technology, complemented by in-house drug substance and product manufacturing capabilities.
RNA therapeutics by Annie Spratt
Developments and News
The company's COVID-19 vaccine candidate received authorization in Japan in 2023 and gained approval in the European Union in 2025. In October 2025, Arcturus entered a licensing and collaboration agreement with CSL Seqirus to utilize its late-stage sa-mRNA vaccine platform for influenza and COVID-19 boosters. Clinical milestones include the initiation of a Phase 1b study for ARCT-810 in ornithine transcarbamylase deficiency patients in June 2020 and ongoing early-stage trials of LUNAR CF for cystic fibrosis (ClinicalTrials.gov: NCT06747858). On October 22, 2025, the company filed a Form 8-K covering items 7.01 and 9.01 and confirmed its next earnings release date for November 6, 2025.
Financial and Strategic Analysis
At market close on October 22, 2025, ARCT shares traded at $10.7461, a decrease of 53.60% year to date, with a trading volume of 969,676 on NASDAQ. Key metrics (trailing twelve months unless otherwise noted) include:
| Metric | Value |
|---|---|
| 52-Week Range | $8.04 – $24.17 |
| Market Cap (intraday) | $628.9 million |
| Revenue | $122.1 million |
| Net Income | −$60.2 million |
| Profit Margin | −49.27% |
| Diluted EPS | −2.22 |
| Total Cash (MRQ) | $196.5 million |
| Debt/Equity (MRQ) | 11.7% |
| Beta (5Y Monthly) | 2.39 |
The company’s cash position supports ongoing research and development efforts, while a modest debt load indicates a disciplined capital structure. The elevated beta reflects greater sensitivity to clinical and market developments.
Market Position and Industry Context
Arcturus competes with established and emerging RNA therapeutics and vaccine developers, including Moderna, BioNTech, and CureVac. Its LUNAR delivery system utilizes targeted lipid-nanoparticle technology, and the STARR platform facilitates self-amplification of mRNA payloads. Strategic partnerships, including the ARCALIS joint venture in Japan and the collaboration with CSL Seqirus, aim to enhance manufacturing scale and extend geographic reach. An extensive patent portfolio of over 500 patents and applications secures the company’s intellectual property across key markets.
tl;dr
On October 22, 2025, ARCT closed at $10.75 (−53.60% YTD) with 969,676 shares traded. The company reported a negative profit margin of 49.27% on $122.1 million in revenue (TTM) and held $196.5 million in cash. An 8-K filing on October 22 included operational updates ahead of a November 6 earnings release. The CSL Seqirus licensing agreement integrates Arcturus’s sa-mRNA platform into influenza and COVID-19 booster programs. Ongoing trials in ornithine transcarbamylase deficiency and cystic fibrosis will influence near-term catalysts amid a high-volatility profile (beta 2.39).